A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy
A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Plozalizumab
C-C chemokine receptor type 2 inhibitor
What it measured
Main measures
•Safety: Safety will be assessed by vital sign measurement, physical examinations, MS relapses, changes in EDSS scores and standard laboratory test results, as well as the incidence of adverse events (AEs) and serious adverse events (SAEs). In addition, MRI scans will be monitored on a continuous basis throughout the study for any change from the pre-treatment phase. Immunogenicity will be asse
Disability progressionRelapsesMRI lesionsImmune responseSafety
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: Each patient must meet all of the following inclusion criteria to be enrolled in the pre-treatment phase of the study: Exclusion: Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objectives of this study are to:
Loading reviews and guidelines…
History
Started
Feb 2005